GlaxoSmithKline Lymerix Cohort Study Adds Two HMOs To Boost Enrollment
GlaxoSmithKline is adding two sites to its Lymerix postmarketing safety study in an effort to increase enrollment in the Phase IV trial.
You may also be interested in...
GlaxoSmithKline's Lymerix will be the subject of an FDA case-control study investigating a potential genetic marker for adverse reactions to the Lyme disease vaccine.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011